{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/ghrp-6",
  "canonicalUrl": "https://thepeptidefield.com/peptides/ghrp-6",
  "record": {
    "slug": "ghrp-6",
    "name": "GHRP-6",
    "aliases": [
      "Growth hormone-releasing peptide 6",
      "Growth hormone-releasing hexapeptide",
      "SKF-110679"
    ],
    "className": "Growth hormone-releasing peptide",
    "family": "Growth signaling",
    "sequenceLabel": "6 amino acids · synthetic growth hormone-releasing peptide",
    "tier": "Emerging",
    "evidenceContext": "Human pharmacology only",
    "statusLine": "No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026",
    "productContext": "FDA's identity record describes the GHRP-6 molecule, not a finished drug product. FDA lists GHRP-6 in compounding safety reviews and in its current 503A category list. Products sold online or made by a compounder need separate proof of identity, quality, and approval.",
    "approvedProducts": [],
    "productRecords": [],
    "indications": [
      "Research on growth-hormone release and human exposure"
    ],
    "profile": {
      "humanOutcomes": {
        "level": "Unclear",
        "note": "Small studies measured short-term hormone responses. They did not establish muscle gain, fat loss, recovery, or other lasting health outcomes."
      },
      "humanPharmacology": {
        "level": "Moderate",
        "note": "Small studies in healthy men show a short-term growth-hormone response. One small early study measured how GHRP-6 moved through the body."
      },
      "safetyKnowledge": {
        "level": "Limited",
        "note": "FDA lists possible immune reactions from peptide impurities or aggregation, plus possible cortisol and blood-sugar effects. Human studies are too small and brief to show uncommon or long-term harms."
      },
      "productCertainty": {
        "level": "Limited",
        "note": "FDA identity records do not establish finished-product quality or approval. Compounded and online products need separate evidence."
      }
    },
    "oneLine": "A six-amino-acid research peptide. Small human studies show short-term growth-hormone changes, not proven muscle, fat-loss, or other lasting health benefits.",
    "reviewedAt": "August 30, 2026",
    "reviewedAtISO": "2026-08-30",
    "reviewHistory": [
      {
        "date": "2026-08-30",
        "note": "Initial brief reviewed FDA identity and compounding records, small human hormone and exposure studies, the FDA approval database, and the 2026 World Anti-Doping Agency list."
      }
    ],
    "whatItIs": "GHRP-6 is a short chain of six amino acids, the small building blocks that make peptides. FDA's identity record lists the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It is designed to affect growth-hormone release. A growth-hormone response is a body measurement. It is not proof of a lasting health benefit.",
    "whatWeKnow": "Small human studies show short-term hormone effects. In 17 healthy men, GHRP-6 increased growth hormone for a short time. Another study in 9 healthy men found that blocking a body signal called GHRH greatly reduced the response. An early study in 9 healthy men measured GHRP-6 exposure in the body. These studies measured hormones and exposure, not muscle gain, fat loss, recovery, or long-term health.",
    "whatWeDoNotKnow": "These studies do not show that GHRP-6 builds muscle, burns fat, speeds recovery, slows aging, or treats a health condition. The studies were small, short, and mainly in healthy men. One study changed the body's GHRH signal to test how the hormone response works. It was not a treatment study. No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. This is a dated database finding, not a claim about every country or future record.",
    "antiDoping": "The 2026 World Anti-Doping Agency list prohibits GHRP-6 at all times, in and out of competition.",
    "antiDopingReview": {
      "status": "Prohibited",
      "detail": "The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. It is prohibited in and out of competition. This page is not personal clearance. Athletes must check the current rules that apply to them.",
      "sourceUrl": "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf",
      "reviewedAtISO": "2026-08-30"
    },
    "safetyBoundary": "FDA lists GHRP-6 among substances that may present safety risks in compounding. FDA notes possible immune reactions from peptide impurities or aggregation, limited safety information, and possible cortisol or blood-sugar effects. This guide gives no dosing, injection, sourcing, or treatment instructions.",
    "relatedSlugs": [
      "ipamorelin",
      "cjc-1295",
      "sermorelin"
    ],
    "claims": [
      {
        "claim": "“GHRP-6 is a six-amino-acid peptide.”",
        "verdict": "Supported with scope",
        "explanation": "FDA's identity record lists GHRP-6 as a hexapeptide, which means six amino acids, and gives its sequence. An identity record does not prove approval, quality, or equivalence between products.",
        "category": "Mechanism and biomarkers",
        "evidenceBasis": "Regulatory or product record",
        "scope": "The FDA-identified GHRP-6 molecule only. This identity fact does not cover every product sold under the name.",
        "sourceUrls": [
          "https://precision.fda.gov/uniisearch/srs/unii/4H7N4I6X6A"
        ]
      },
      {
        "claim": "“GHRP-6 can raise growth hormone in short human studies.”",
        "verdict": "Supported with scope",
        "explanation": "Small studies in healthy men measured short-term increases in growth hormone after GHRP-6. One study found that the response depended in large part on GHRH, another body signal. These are hormone measurements, not proof of treatment benefit.",
        "category": "Mechanism and biomarkers",
        "evidenceBasis": "Human pharmacology",
        "scope": "Small, short studies in healthy men; hormone response only, not muscle, fat loss, recovery, or other health outcomes.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/2543692/",
          "https://pubmed.ncbi.nlm.nih.gov/9543138/"
        ]
      },
      {
        "claim": "“A growth-hormone response proves that GHRP-6 builds muscle or burns fat.”",
        "verdict": "Not established",
        "explanation": "A hormone response is not the same as a lasting health outcome. The reviewed human studies did not establish muscle gain or fat loss.",
        "category": "Body composition",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "Muscle, fat-loss, and other lasting outcomes; the reviewed studies measured hormones or exposure only.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/2543692/",
          "https://pubmed.ncbi.nlm.nih.gov/23099431/"
        ]
      },
      {
        "claim": "“GHRP-6 is FDA-approved in the United States.”",
        "verdict": "Misleading",
        "explanation": "No FDA-approved human GHRP-6 product was identified in the checked U.S. databases as of August 30, 2026. FDA's substance identity record does not mean approval. This is a dated database finding, not a claim about every country or future record.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "U.S. human drug records checked on August 30, 2026.",
        "sourceUrls": [
          "https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases",
          "https://precision.fda.gov/uniisearch/srs/unii/4H7N4I6X6A"
        ]
      },
      {
        "claim": "“A compounded GHRP-6 product is FDA-approved.”",
        "verdict": "Misleading",
        "explanation": "FDA says it does not approve compounded drugs. Its current 503A list puts GHRP-6 in Category 3. This means the nomination did not have enough support. FDA also lists safety concerns for 503B compounding. A 2019 warning letter said GHRP-6 did not meet the 503A rules in that case.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "U.S. FDA records about compounded GHRP-6, checked August 30, 2026. This is not legal advice about one product.",
        "sourceUrls": [
          "https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act",
          "https://www.fda.gov/media/94155/download?attachment=",
          "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
          "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019",
          "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
        ]
      },
      {
        "claim": "“GHRP-6 is allowed in tested sport.”",
        "verdict": "Misleading",
        "explanation": "The 2026 WADA Prohibited List names GHRP-6 under growth hormone-releasing factors. WADA prohibits it at all times, both in and out of competition.",
        "category": "Performance and recovery",
        "evidenceBasis": "Regulatory or product record",
        "scope": "Athletes subject to the 2026 WADA Prohibited List; rules can differ by sport and organization.",
        "sourceUrls": [
          "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf"
        ]
      }
    ],
    "sources": [
      {
        "label": "GHRP-6 substance identity record (UNII 4H7N4I6X6A)",
        "publisher": "U.S. Food and Drug Administration Global Substance Registration System",
        "url": "https://precision.fda.gov/uniisearch/srs/unii/4H7N4I6X6A",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Growth hormone response to GHRP-6 in healthy men",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/2543692/",
        "kind": "Human pharmacology",
        "year": 1989,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "GHRP-6 growth hormone response and GHRH dependence",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/9543138/",
        "kind": "Human pharmacology",
        "year": 1998,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "GHRP-6 exposure study in healthy men",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/23099431/",
        "kind": "Human pharmacology",
        "year": 2012,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Drug approvals and databases",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Bulk drug substances used in compounding under section 503A",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "503A Category 3 bulk drug substances nominated without adequate support",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/media/94155/download?attachment=",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Bulk drug substances that may present significant compounding safety risks",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "United Pharmacy warning letter",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019",
        "kind": "Regulatory",
        "year": 2019,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Human drug compounding: FDA questions and answers",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "2026 Prohibited List",
        "publisher": "World Anti-Doping Agency",
        "url": "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf",
        "kind": "Anti-doping",
        "year": 2026,
        "accessedAt": "2026-08-30"
      }
    ]
  }
}